CA1120399A
Expired / Lapsed
CA
⏱️ 0.0 years remaining
Pharmaceutical compositions for treatment of tumor cells
Assignee: Université de Sherbrooke
•
Filing: 1979-09-28
•
Granted: 1982-03-23
•
Expires: 1999-09-28
Abstract
Abstract ABSTRACT The present invention relates to a pharmaceutic- al composition effective for enhancing the capacity of a host to reject a large number of tumor cells, retarding growth in tumor size or in inducing hemorrhagic necrosis, which comprises a fatty acid ester of a mono or di- saccharide, in admixture with a pharmaceutically accept- able carrier, the fatty acid having 12 to 18 carbon atoms and the mono or disaccharide being selected from maltose, galactose, glucose, mannose, arabinose and cellobiose.
Inventors
- 👤 Vijai N. Nigam
- 👤 Carlos A. Brailovsky
Bibliographic Details
Application Number
—
Jurisdiction
CA
Data Source
google_patents
Last Synchronized
2026-11-09 05:58
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/7004
Claims Analysis
Total Claims: 3
Claim 1
Independent Claim
90 words
The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows: 1. A pharmaceutical composition effective for enhancing the capacity of a host to reject a large number of tumor cells, retarding growth in tumor size or in inducing hemorrhagic necrosis, which comprises a fatty acid ester of a mono or disaccharide, in admixture with a pharmaceutically acceptable carrier, the fatty acid having 12 to 18 carbon atoms and the mono or disaccharide being selected from maltose, galactose, glucose, mannose, arabinose and cellobiose.
Claim 2
Dependent Claim
26 words
The pharmaceutical composition of Claim 1, which comprises a dosage unit containing from 0.05 to 0.5 mg/kg of fatty acid ester of the mono or disaccharide.
Claim 3
Dependent Claim
19 words
The pharmaceutical composition of Claims 1 or 2, wherein the fatty acid ester of the disaccharide is maltose tetrapalmitate.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.